Complete Filing Data
Quoin Pharmaceuticals, Ltd. reported Stockholders Equity of $13.12 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Quoin Pharmaceuticals, Ltd. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$15.8M | -$9.0M | -$8.7M | -$9.4M | -$21.5M | -$2.1M | -$1.6M | -$20.1M | -$28.2M | -$15.3M | -$10.2M |
| Research And Development Expense | $9.8M | $3.6M | $3.3M | $2.7M | $1.6M | $244.2K | $45.7K | $13.5M | -$11.5M | $8.3M | $5.9M |
| Selling General And Administrative Expense | $6.5M | $5.9M | $6.1M | $6.6M | $4.5M | $1.4M | $1.5M | ||||
| Amortization Of Intangible Assets | $100.0K | $100.0K | $103.7K | $104.0K | $104.0K | $104.0K | $20.7K | ||||
| Nonoperating Income Expense | $486.1K | $566.0K | $691.9K | -$123.8K | -$15.4M | -$425.4K | |||||
| Net Income Loss Available To Common Stockholders Basic | -$8.7M | -$9.4M | -$21.5M | ||||||||
| Profit Loss From Operating Activities | -$4.4M | -$22.3M | -$29.2M | -$24.4M | -$15.9M | -$10.1M | |||||
| Adjustments For Reconcile Profit Loss | $2.9M | -$2.3M | -$4.4M | $9.4M | $695.0K | $1.5M | |||||
| General And Administrative Expense | $2.5M | $10.2M | $15.7M | -$12.9M | $8.0M | $4.2M | |||||
| Revenue From Contract With Customer Excluding Assessed Tax | $0.00 | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$3.9M | -$3.7M | -$3.8M | -$2.3M | -$2.0M | -$2.3M | -$1.9M | -$2.1M | -$2.6M | -$3.0M | -$2.7M | -$1.7M |
| Research And Development Expense | $2.3M | $2.1M | $2.4M | $1.1M | $587.5K | $885.3K | $758.8K | $625.1K | $1.1M | $745.5K | $726.7K | $587.6K |
| Selling General And Administrative Expense | $1.7M | $1.7M | $1.6M | $1.4M | $1.5M | $1.6M | $1.4M | $1.6M | $1.7M | $1.6M | $1.9M | $1.6M |
| Amortization Of Intangible Assets | $25.0K | $25.0K | $25.0K | $25.0K | $25.0K | $25.0K | $26.0K | $26.0K | $26.0K | $26.0K | $26.0K | $26.0K |
| Nonoperating Income Expense | $71.8K | $97.2K | $145.0K | $178.1K | $163.1K | $131.0K | $198.5K | $153.1K | $172.5K | -$702.0K | $493.2K | |
| Net Income Loss Available To Common Stockholders Basic | -$1.9M | -$3.1M | ||||||||||
| Profit Loss From Operating Activities | ||||||||||||
| Adjustments For Reconcile Profit Loss | ||||||||||||
| General And Administrative Expense | ||||||||||||
| Revenue From Contract With Customer Excluding Assessed Tax |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $13.1M | $9.2M | $5.7M | $7.4M | $657.0K | -$6.6M | -$4.5M | -$3.0M | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $3.8M | $3.6M | $2.4M | $2.9M | $7.5M | $323.8K | $40.00 | |||||
| Assets | $20.4M | $15.7M | $12.2M | $14.5M | $9.4M | $1.4M | $21.3M | $20.6M | $30.4M | $33.9M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $1.2M | -$459.4K | -$4.6M | $7.2M | $323.8K | -$40.00 | ||||||
| Repayments Of Related Party Debt | $600.0K | $600.0K | $600.0K | $600.0K | $304.5K | $50.0K | ||||||
| Retained Earnings Accumulated Deficit | -$71.0M | -$55.2M | -$46.2M | -$37.5M | -$28.1M | -$6.6M | ||||||
| Net Proceeds From Issuance Of Common Stock | $11.6M | $5.8M | $14.9M | $10.1M | ||||||||
| Liabilities And Stockholders Equity | $20.4M | $15.7M | $12.2M | $14.5M | $9.4M | $1.4M | ||||||
| Liabilities | $7.3M | $6.5M | $6.5M | $7.1M | $8.7M | $8.0M | ||||||
| Intangible Assets Net Excluding Goodwill | $383.3K | $483.3K | $583.3K | $704.6K | $808.6K | $912.6K | ||||||
| Cash And Cash Equivalents At Carrying Value | $3.8M | $3.6M | $2.4M | $2.9M | $7.5M | $323.8K | ||||||
| Assets Current | $20.0M | $14.9M | $11.3M | $13.4M | $8.2M | $465.2K | ||||||
| Accrued Liabilities Current | $2.5M | $1.5M | $1.3M | $1.2M | $1.7M | $960.8K | ||||||
| Cash And Cash Equivalents | $5.3M | $18.1M | $17.8M | $13.7M | $6.3M | $3.9M | $2.1M | |||||
| Accounts Payable Current | $1.3M | $905.7K | $526.5K | $605.6K | $923.2K | |||||||
| Interest Payable Current And Noncurrent | $1.1M | $1.1M | $743.8K | $47.0K | ||||||||
| Liabilities Current | $5.5M | $4.2M | $3.6M | $3.5M | $4.6M | |||||||
| Equity | $13.1M | $9.2M | $5.7M | $7.4M | $657.0K | -$6.6M | -$4.5M | -$3.0M | ||||
| Treasury Stock Shares Acquired | 0.00 | 45.00 | 2.6M | |||||||||
| Common Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | ||||||||
| Investments | $8.3M | $10.0M | ||||||||||
| Treasury Stock Common Value | $2.9M | $2.9M | ||||||||||
| Other Liabilities Noncurrent | $1.7M | $2.3M | $2.9M | $3.5M | ||||||||
| Other Liabilities Current | $600.0K | $600.0K | $600.0K | $600.0K | ||||||||
| Unrealized Gain Loss On Investments | $251.6K | $489.1K | $93.8K | |||||||||
| Operating Activities For Changes In Asset And Liability | -$414.0K | -$1.3M | $841.0K | $877.0K | $210.0K | $1.0M | ||||||
| Cash Flows From Used In Operating Activities | -$15.5M | -$20.3M | -$23.6M | -$17.8M | -$14.4M | -$7.7M | ||||||
| Cash Flows From Used In Financing Activities | $13.4M | $21.9M | $12.8M | $15.8M | $34.9M | $6.4M | ||||||
| Adjustments For Increase Decrease In Other Operating Payables | -$193.0K | -$1.7M | $798.0K | $407.0K | $1.3M | $1.3M | ||||||
| Adjustments For Decrease Increase In Trade And Other Receivables | $207.0K | $385.0K | $43.0K | $470.0K | -$1.0M | -$328.0K | ||||||
| Adjustments For Increase Decrease In Trade And Other Payables | $2.7M | -$8.6M | -$7.7M | $3.0M | -$1.2M | |||||||
| Realized And Accrued Interest Income | $558.5K | $694.6K | $95.7K | |||||||||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $329.0K | $123.0K | $656.0K | $266.0K | $1.3M | $332.0K | ||||||
| Cash Flows From Used In Investing Activities | -$288.0K | -$108.0K | $13.7M | $10.1M | -$18.0M | $3.2M | ||||||
| Reclassification Of Warrant Liability To Equity Upon Issuance Of Exchange Warrants | $296.4K | $12.4M | ||||||||||
| Property Plant And Equipment | $384.0K | $1.3M | $1.5M | $1.3M | $1.4M | $1.3M | ||||||
| Trade And Other Current Payables To Trade Suppliers | $121.0K | $158.0K | $887.0K | $1.7M | $1.4M | |||||||
| Retained Earnings | -$37.0M | -$100.9M | -$84.1M | -$63.9M | -$35.7M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | -$1.2M | $2.6M | $5.9M | $5.4M | $7.5M | $9.1M | $7.4M | $9.1M | $10.9M | $9.2M | -$3.2M | -$729.4K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $1.8M | $1.7M | $3.8M | $3.1M | $2.8M | $1.8M | $3.2M | $4.8M | $3.4M | $5.2M | $2.7M | $5.2M | |
| Assets | $6.4M | $8.9M | $13.0M | $11.4M | $14.1M | $16.1M | $15.1M | $16.7M | $18.5M | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $198.8K | -$567.7K | $511.2K | -$2.3M | |||||||||
| Repayments Of Related Party Debt | $150.0K | $150.0K | $100.0K | $150.0K | |||||||||
| Retained Earnings Accumulated Deficit | -$66.6M | -$62.7M | -$59.0M | -$52.9M | -$50.5M | -$48.5M | -$44.2M | -$42.2M | -$40.1M | ||||
| Net Proceeds From Issuance Of Common Stock | $173.0K | $5.5M | $5.8M | ||||||||||
| Liabilities And Stockholders Equity | $6.4M | $8.9M | $13.0M | $11.4M | $14.1M | $16.1M | $15.1M | $16.7M | $18.5M | ||||
| Liabilities | $7.6M | $6.4M | $7.0M | $5.9M | $6.6M | $7.0M | $7.7M | $7.6M | $7.5M | ||||
| Intangible Assets Net Excluding Goodwill | $408.3K | $433.3K | $458.3K | $508.3K | $533.3K | $558.3K | $626.5K | $652.5K | $678.6K | ||||
| Cash And Cash Equivalents At Carrying Value | $1.8M | $1.7M | $3.8M | $3.1M | $2.8M | $1.8M | $3.2M | $4.8M | $3.4M | ||||
| Assets Current | $6.0M | $8.5M | $12.5M | $10.5M | $13.2M | $15.3M | $14.1M | $15.7M | $17.4M | ||||
| Accrued Liabilities Current | $2.2M | $1.7M | $2.5M | $1.5M | $1.4M | $2.1M | $2.6M | $1.8M | $2.1M | ||||
| Cash And Cash Equivalents | |||||||||||||
| Accounts Payable Current | $1.9M | $873.7K | $644.1K | $222.6K | $819.7K | $358.5K | $240.0K | $707.9K | $281.1K | ||||
| Interest Payable Current And Noncurrent | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | ||||
| Liabilities Current | $5.8M | $4.3M | $4.9M | $3.5M | $4.0M | $4.2M | $4.6M | $4.4M | $4.2M | ||||
| Equity | -$1.2M | $2.6M | $5.9M | $5.4M | $7.5M | $9.1M | $7.4M | $9.1M | $10.9M | $9.2M | -$3.2M | -$729.4K | |
| Treasury Stock Shares Acquired | 2.6M | ||||||||||||
| Common Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Investments | $3.6M | $6.1M | $7.7M | $10.4M | $7.2M | $9.7M | $12.9M | $10.8M | $10.7M | $13.6M | |||
| Treasury Stock Common Value | $2.9M | $2.9M | $2.9M | ||||||||||
| Other Liabilities Noncurrent | $1.9M | $2.0M | $2.2M | $2.5M | $2.6M | $2.8M | $3.1M | $3.2M | |||||
| Other Liabilities Current | $600.0K | $600.0K | $600.0K | $600.0K | $600.0K | $600.0K | $600.0K | $725.0K | |||||
| Unrealized Gain Loss On Investments | $67.1K | $97.0K | $133.6K | ||||||||||
| Operating Activities For Changes In Asset And Liability | |||||||||||||
| Cash Flows From Used In Operating Activities | |||||||||||||
| Cash Flows From Used In Financing Activities | |||||||||||||
| Adjustments For Increase Decrease In Other Operating Payables | |||||||||||||
| Adjustments For Decrease Increase In Trade And Other Receivables | |||||||||||||
| Adjustments For Increase Decrease In Trade And Other Payables | |||||||||||||
| Realized And Accrued Interest Income | $62.3K | $103.2K | $144.9K | $146.4K | $165.3K | $137.5K | $196.4K | $187.6K | $152.1K | ||||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | |||||||||||||
| Cash Flows From Used In Investing Activities | |||||||||||||
| Reclassification Of Warrant Liability To Equity Upon Issuance Of Exchange Warrants | $296.4K | ||||||||||||
| Property Plant And Equipment | |||||||||||||
| Trade And Other Current Payables To Trade Suppliers | |||||||||||||
| Retained Earnings |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$13.5M | -$7.9M | -$7.9M | -$8.5M | -$5.7M | -$1.3M | -$1.3M | ||||
| Net Cash Provided By Used In Financing Activities | $18.0M | $11.0M | $5.2M | $14.0M | $13.5M | $1.8M | $1.3M | ||||
| Net Cash Provided By Used In Investing Activities | -$4.3M | -$1.9M | $2.2M | -$10.1M | -$625.0K | -$125.0K | |||||
| Increase Decrease In Accounts Payable And Accrued Expenses | $53.9K | -$217.8K | $1.3M | $227.3K | $240.8K | ||||||
| Increase Decrease In Prepaid Expense | $92.8K | $278.1K | -$41.5K | -$123.5K | $715.5K | ||||||
| Share Based Compensation | $1.1M | $1.3M | $1.1M | $764.0K | |||||||
| Payments For Previous Intangible Asset Acquisition | $250.0K | $625.0K | $125.0K | ||||||||
| Payments To Acquire Investments | $12.3M | $17.3M | $18.1M | $9.9M | |||||||
| Increase Decrease In Cash And Cash Equivalents | -$1.1M | $297.0K | $4.1M | $7.5M | $2.4M | $1.8M | |||||
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | $393.0K | -$1.1M | $1.2M | -$679.0K | -$134.0K | -$70.0K | |||||
| Proceeds From Issuing Shares | 9.2M | 22.4M | 12.4M | 14.4M | 34.9M | 6.3M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$2.6M | -$1.4M | -$1.7M | -$2.1M |
| Net Cash Provided By Used In Financing Activities | $23.0K | $5.3M | $5.7M | -$150.0K |
| Net Cash Provided By Used In Investing Activities | $2.8M | -$4.5M | -$3.5M | -$50.0K |
| Increase Decrease In Accounts Payable And Accrued Expenses | $642.5K | $585.0K | $162.1K | |
| Increase Decrease In Prepaid Expense | -$225.0K | -$16.1K | -$117.7K | -$206.0K |
| Share Based Compensation | $360.4K | $306.3K | $261.5K | |
| Payments For Previous Intangible Asset Acquisition | $50.0K | |||
| Payments To Acquire Investments | $9.6M | $13.5M | ||
| Increase Decrease In Cash And Cash Equivalents | ||||
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | ||||
| Proceeds From Issuing Shares |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| Common Stock Shares Authorized | 5.00B | 100.0M | 100.0M | 8.3M | 500.00B | 12.50B | |||||
| Common Stock Shares Outstanding | 52.4M | 8.9M | 987.2K | 403.9K | 3.35B | 1.20B | |||||
| Common Stock Shares Issued | 52.4M | 8.9M | 987.2K | 403.9K | 3.35B | 1.20B | |||||
| Basic And Diluted Earnings Loss Per Share | $0.05 | $0.08 | $0.16 | $0.25 | $0.17 | $0.14 | |||||
| Weighted Average Shares | 368.1M | 212.6M | 129.4M | 112.0M | 91.1M | 74.5M | |||||
| Earnings Per Share Diluted | $-0.01 | $-0.70 | $-0.52 | ||||||||
| Earnings Per Share Basic | $-0.01 | $-0.70 | $-0.52 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Authorized | 5.00B | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 8.3M | 500.00B | 500.00B | 833.3K | 833.3K |
| Common Stock Shares Outstanding | 20.6M | 20.6M | 20.6M | 5.0M | 4.0M | 3.8M | 987.2K | 59.23B | 59.23B | ||
| Common Stock Shares Issued | 20.6M | 20.6M | 20.6M | 5.0M | 4.0M | 3.8M | 987.2K | 59.23B | 59.23B | ||
| Basic And Diluted Earnings Loss Per Share | |||||||||||
| Weighted Average Shares | |||||||||||
| Earnings Per Share Diluted | |||||||||||
| Earnings Per Share Basic |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Costs And Expenses | $16.3M | $9.5M | $9.4M | $9.3M | $6.1M | $1.7M | $1.6M | ||||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $1.1M | $1.3M | $1.1M | $764.0K | |||||||
| Additional Paid In Capital | $84.1M | $64.4M | $51.9M | $47.9M | $31.7M | $100.00 | $31.4M | $95.1M | |||
| Unrealized Gain Loss On Derivatives | $4.0K | $7.5K | -$2.7K | $1.3K | |||||||
| Fair Value Adjustment Of Warrants | -$77.2K | $12.8M | |||||||||
| Stock Issued During Period Value New Issues | $15.1M | $11.2M | $5.8M | $14.9M | $17.0M | ||||||
| Prepaid Expense Noncurrent | $300.0K | $300.0K | $383.4K | $300.0K | |||||||
| Offering Expenses Associated With Warrant Modification | $1.7M | $238.2K | $491.6K | ||||||||
| Prepaid Expense Current | $715.5K | ||||||||||
| Adjustments For Sharebased Payments | $738.0K | $2.7M | $4.5M | $5.4M | $1.6M | $1.3M | |||||
| Adjustments For Depreciation And Amortisation Expense | $109.0K | $373.0K | $459.0K | $372.0K | $350.0K | $71.0K | |||||
| Finance Costs | $4.1M | $1.5M | $20.0K | $3.9M | $33.0K | $79.0K | |||||
| Interest Income Other | $95.7K | ||||||||||
| Adjustments To Additional Paid In Capital Warrant Issued | $296.4K | $12.4M | |||||||||
| Treasury Shares | 2.9M | 9.4M | 9.4M | 9.4M | 9.4M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Costs And Expenses | $4.0M | $3.8M | $4.0M | $2.5M | $2.1M | $2.5M | $2.1M | $2.3M | $2.8M | $2.3M | $2.7M | $2.2M | |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $182.2K | $321.5K | $360.4K | $313.1K | $313.1K | $306.3K | $268.5K | $264.4K | $261.5K | $267.3K | $229.4K | ||
| Additional Paid In Capital | $65.4M | $65.2M | $64.9M | $58.3M | $58.0M | $57.7M | $54.5M | $54.2M | $54.0M | ||||
| Unrealized Gain Loss On Derivatives | $9.5K | -$6.0K | $126.00 | $31.7K | -$2.2K | -$6.5K | $2.1K | -$34.5K | $20.4K | -$3.1K | |||
| Fair Value Adjustment Of Warrants | -$77.2K | ||||||||||||
| Stock Issued During Period Value New Issues | $5.5M | $5.8M | $14.9M | ||||||||||
| Prepaid Expense Noncurrent | $383.4K | $300.0K | $300.0K | $300.0K | $383.4K | $383.4K | |||||||
| Offering Expenses Associated With Warrant Modification | $209.2K | $238.2K | |||||||||||
| Prepaid Expense Current | $159.9K | $234.2K | $398.9K | $516.6K | |||||||||
| Adjustments For Sharebased Payments | |||||||||||||
| Adjustments For Depreciation And Amortisation Expense | |||||||||||||
| Finance Costs | |||||||||||||
| Interest Income Other | $196.4K | $187.6K | $152.1K | $15.1K | |||||||||
| Adjustments To Additional Paid In Capital Warrant Issued | $296.4K | ||||||||||||
| Treasury Shares |
Most recent annual filing with the SEC: March 26, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.